Selected article for: "clinical trial and promising development"

Author: Hussen, Jamal; Kandeel, Mahmoud; Hemida, Maged Gomaa; Al-Mubarak, Abdullah I. A.
Title: Antibody-Based Immunotherapeutic Strategies for COVID-19
  • Cord-id: kv57osto
  • Document date: 2020_11_5
  • ID: kv57osto
    Snippet: Global efforts to contain the coronavirus disease-2019 (COVID-19) include the development of novel preventive vaccines and effective therapeutics. Passive antibody therapies using convalescent plasma, SARS-CoV-2 (Severe-Acute-Respiratory-Syndrome-Corona-Virus-2)-specific neutralizing antibodies (NAbs), and the development of monoclonal antibodies (MAbs) are among the most promising strategies for prophylaxis and treatment of SARS-CoV-2 infections. In addition, several immunomodulatory antibodies
    Document: Global efforts to contain the coronavirus disease-2019 (COVID-19) include the development of novel preventive vaccines and effective therapeutics. Passive antibody therapies using convalescent plasma, SARS-CoV-2 (Severe-Acute-Respiratory-Syndrome-Corona-Virus-2)-specific neutralizing antibodies (NAbs), and the development of monoclonal antibodies (MAbs) are among the most promising strategies for prophylaxis and treatment of SARS-CoV-2 infections. In addition, several immunomodulatory antibodies acting via several mechanisms to boost the host immune defense against SARS-CoV-2 infection as well as to avoid the harmful overreaction of the immune system are currently under clinical trial. Our main objective is to present the current most up-to-date progress in some clinical trials registered at ClinicalTrials.gov. We highlight the pros and pitfalls of several SARS-CoV-2 antibody-based immunotherapeutics.

    Search related documents:
    Co phrase search for related documents
    • acid inducible and adaptive immune response: 1, 2, 3, 4, 5
    • acid inducible gene and activation induce: 1, 2
    • acid inducible gene and adaptive immune response: 1, 2, 3, 4, 5
    • activate helper and adaptive immune response: 1
    • activation co and acute ards respiratory distress syndrome: 1
    • activation induce and acute ards respiratory distress syndrome: 1, 2
    • activation induce and adaptive immune response: 1, 2, 3, 4
    • activation induce and additional benefit: 1
    • active immunization and adaptive immune response: 1, 2
    • active immunization and adcc cellular cytotoxicity: 1
    • acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and adaptive immune response mount: 1
    • acute ards respiratory distress syndrome and additional benefit: 1, 2